The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Why preventive mastectomy isn't offered to everyone at risk

2.

Financial hardship common in patients with cancer

3.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

4.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

5.

Severe obesity associated with reduced prevalence of recommended cancer screenings


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot